You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

adrenaclick Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Adrenaclick patents expire, and what generic alternatives are available?

Adrenaclick is a drug marketed by Impax and is included in one NDA.

The generic ingredient in ADRENACLICK is epinephrine. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Adrenaclick

A generic version of adrenaclick was approved as epinephrine by BPI LABS on July 29th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for adrenaclick?
  • What are the global sales for adrenaclick?
  • What is Average Wholesale Price for adrenaclick?
Drug patent expirations by year for adrenaclick
Drug Prices for adrenaclick

See drug prices for adrenaclick

Recent Clinical Trials for adrenaclick

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of LouisvillePhase 4
Arthroplasty Foundation, Inc.Phase 4
NYU Langone HealthN/A

See all adrenaclick clinical trials

US Patents and Regulatory Information for adrenaclick

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-003 Nov 25, 2009 BX RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-004 Nov 25, 2009 BX RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for adrenaclick

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Impax ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-003 Nov 25, 2009 ⤷  Sign Up ⤷  Sign Up
Impax ADRENACLICK epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-004 Nov 25, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for adrenaclick

See the table below for patents covering adrenaclick around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 9531235 ⤷  Sign Up
China 101072595 Medicine injection devices and methods ⤷  Sign Up
Canada 2163005 SYSTEME D'INJECTION D'URGENCE, RECHARGEABLE, AUTOMATIQUE OU MANUEL (RELOADABLE AUTOMATIC OR MANUAL EMERGENCY INJECTION SYSTEM) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2006062788 ⤷  Sign Up
Australia 1994295 ⤷  Sign Up
Canada 2826821 PROCEDES ET DISPOSITIFS D'INJECTION DE MEDICAMENTS (MEDICINE INJECTION DEVICES AND METHODS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.